A preliminary paper indicates that lowering widely prescribed, FDA-approved dosages of highly toxic oncology medications could potentially correlate with a slight decrease in devastating side effects.
The study, which relied heavily on self-reported data and observational models, examined a small cohort of patients who deviated from the prevailing medical protocol of receiving the absolute maximum survivable amount of cytotoxic chemicals. While experts caution against drawing premature conclusions from a single dataset, early findings point to a statistically significant association between putting a smaller volume of cellular poison into a human bloodstream and that patient experiencing fewer instances of catastrophic organ failure.
While the data is intriguing, we must remember that correlation does not equal causation, and it remains entirely possible that patients receiving half the volume of severe, cell-destroying chemicals are simply experiencing a placebo effect of not having their organs actively liquidated.
The FDA has subsequently issued guidance reminding oncologists that the current dosage regimens—which generate billions of dollars annually for pharmaceutical manufacturers—were established through rigorous, industry-funded clinical trials specifically designed to identify the exact milligram threshold just before a patient's body completely gives out. Representatives from the NIH added that halving a prescription simply because the patient appears to be eradicating their tumors just fine would represent a drastic, unverified departure from standard therapeutic models.
At press time, researchers warned that more research is needed to determine whether avoiding personal bankruptcy from slightly cheaper treatment regimens might also serve as an independent risk factor for prolonged survival. The broader medical community strongly recommends that patients consult their oncology providers to weigh the theoretical risks before deciding they would like to be poisoned a little bit less.